Evidence map›Paper›PMID 20869318›Full record

ReviewTrends in molecular medicine2010

Nanosensors and nanomaterials for monitoring glucose in diabetes.

Kevin J Cash, Heather A Clark

Open access · greenAbstract readEvaluation StudyReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in molecular medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 355 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Selective Design of Mesoporous BiSmall (Weinheim an der Bergstrasse, Germany) · 2025
    Article
  8. Diabetology and Nanotechnology: A Compelling Combination.Recent patents on nanotechnology · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Nanotheranostics: application of nanosensors in diabetes management.Journal of diabetes and metabolic disorders · 2023
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kevin J CashDepartment of Pharmaceutical Sciences, Northeastern University, 110 Mugar Life Sciences Building, 360 Huntington Avenue, Boston, MA 02115, USA.
Heather A Clark
Northeastern University · US

Funding

Ion Selective Quantum Dots for Intracellular Mapping of Sodium Sparks in Cardiac R01GM084366 · NIGMS · NORTHEASTERN UNIVERSITY · PI CLARK, HEATHER A · 2008 to 2012
$1.3M
NIGMS NIH HHS R01 GM084366
6 · The paper itself

Abstract

Worldwide, diabetes is a rapidly growing problem that is managed at the individual level by monitoring and controlling blood glucose levels to minimize the negative effects of the disease. Because of limitations in diagnostic methods, significant research efforts are focused on developing improved methods to measure glucose. Nanotechnology has impacted these efforts by increasing the surface area of sensors, improving the catalytic properties of electrodes and providing nanoscale sensors. Here, we discuss developments in the past several years on both nanosensors that directly measure glucose and nanomaterials that improve glucose sensor function. Finally, we discuss challenges that must be overcome to apply these developments in the clinic.

Indexed as

NanostructuresAnimalsBiosensing TechniquesBlood GlucoseDiabetes MellitusHumansNanotechnologyBlood Glucose

Identifiers

PMID20869318
PMCPMC2996880
OpenAlexW2038055857

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.